Ernexa Therapeutics (ERNAW) Amortization of Deferred Charges (2015 - 2024)
Ernexa Therapeutics' (ERNAW) quarterly Amortization of Deferred Charges came in at $78000.0 in Q1 2026, up 52.94% YoY from $51000.0 in Q1 2025, and up 39.29% on a QoQ basis from $56000.0 in Q4 2025.
Powered by 
Analysis
Ernexa Therapeutics (ERNAW) Amortization of Deferred Charges (2015 - 2024) Analysis & Trends
Ernexa Therapeutics (ERNAW) has 11 years of Amortization of Deferred Charges data on file, last reported at $78000.0 in Q1 2026.
- Quarterly Amortization of Deferred Charges rose 52.94% year-over-year to $78000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $225000.0 (down 95.4% YoY) and the FY2025 annual result came in at $198000.0, down 96.24% from the prior year.
- Amortization of Deferred Charges climbed to $78000.0 in Q1 2026, from $56000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $3.8 million in Q4 2024 to a low of -$186000.0 in Q3 2022.
- A 5-year average of $403466.7 and a median of $84000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges sank 297.87% — and 2024, when it jumped 1417.53%.
- Tracing ERNAW's Amortization of Deferred Charges over 5 years: stood at -$186000.0 in 2022, then soared by 234.95% to $251000.0 in 2023, then jumped by 1417.53% to $3.8 million in 2024, then tumbled by 98.53% to $56000.0 in 2025, then surged by 39.29% to $78000.0 in 2026.
- The last three Amortization of Deferred Charges figures came in at $78000.0 (Q1 2026), $56000.0 (Q4 2025), and $53000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Ernexa Therapeutics | 67,312.70 | 67,312.70 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 3.11 Mn |
| Sep 30, 2024 | 1.23 Mn |
| Jun 30, 2024 | 500,000.00 |
| Mar 31, 2024 | 445,000.00 |
| Dec 31, 2023 | 251,000.00 |
| Sep 30, 2023 | 100,000.00 |
| Dec 31, 2020 | 2,000.00 |
| Mar 31, 2020 | 3,000.00 |
| Dec 31, 2019 | 2,000.00 |
| Sep 30, 2019 | 2,000.00 |
| Jun 30, 2019 | 2,000.00 |
| Mar 31, 2019 | 3,000.00 |
| Dec 31, 2018 | 2,000.00 |
| Sep 30, 2018 | 40,000.00 |
| Jun 30, 2018 | 9,000.00 |
| Mar 31, 2018 | 8,000.00 |
| Dec 31, 2017 | 21,000.00 |
| Sep 30, 2017 | 13,000.00 |
| Jun 30, 2017 | 14,000.00 |
| Mar 31, 2017 | 12,000.00 |